skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreProduct loginProductLogin
Global Search Configuration

This important white paper provides an analysis of kinase inhibitor trials for the management of rheumatoid arthritis, which have been discontinued and why, and which hold promise for easing the symptoms of this chronically progressive disease.

Highlights in this white paper include:

  • Phase II to III kinase inhibitor trials in RA initiated since mid-2010
  • Kinase inhibitors in active late stage development for RA
  • Kinase inhibitors discontinued for RA, and why
  • Trial sponsors who are having the greatest success and more

 

 

 

July-2015_Kinese-Inhibitors-in-RA_Gunilla-Sturrock
Download white paper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact Sales

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now